United Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT01477333
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1333
- Registration Number
- NCT01266265
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Northwestern Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT01172496
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
- Conditions
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT01165476
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT01153386
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
- Conditions
- Interventions
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2012-05-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT01131845
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT01104870
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of California Los Angeles Pulmonary Division, Los Angeles, California, United States
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT01028651
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Emory Univeristy, Atlanta, Georgia, United States
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 894
- Registration Number
- NCT01027949
- Locations
- 🇩🇪
Zentrum für Lungenhochdruck Thoraxklinik am Universitätsklinikum Heidelberg, Hamburg, Germany
🇮🇹Dipartimento di Scienze Cardiovascolari, Respiratorie e Morfologiche, Rome, Italy
🇲🇽Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Mexico
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT00969722
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Children's Hospital at Montefiore, Bronx, New York, United States